Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Functionalized nanoparticles and methods of use thereof

a technology of functionalized nanoparticles and nanoparticles, which is applied in the field of functionalized nanoparticles, can solve problems such as severe limitations in the therapeutic efficacy

Inactive Publication Date: 2013-08-01
RGT UNIV OF MINNESOTA
View PDF2 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new type of nanoparticle that can be attached to other molecules, such as proteins. These nanoparticles can be used to treat diseases associated with fibrin, such as cancer and myocardial infarction. The nanoparticle is made up of a polymer and other components that are attached to it. The patent also describes a compound that can be used to make the nanoparticle. Overall, the patent provides a technical solution for delivering therapeutic agents to animals, including humans.

Problems solved by technology

Inefficient transport of drug delivery systems through tumor extracellular matrix (ECM) severely limits therapeutic efficacy.
This is a critical problem because these poorly-perfused regions (which have low pH and low pO2) harbor the most aggressive and drug-resistant tumor cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Functionalized nanoparticles and methods of use thereof
  • Functionalized nanoparticles and methods of use thereof
  • Functionalized nanoparticles and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0106]Inefficient transport of drug delivery systems through tumor extracellular matrix (ECM) severely limits therapeutic efficacy. Tumors are characterized by the presence of a neo-vasculature that is underdeveloped and leaky. This leads to deposition of fibrin, a key ingredient of blood clot, within the tumor matrix (M. Schafer, S. Werner, Nat Rev Mol Cell Biol 9, 628 (2008)). The presence of fibrin is an important cause of elevated interstitial fluid pressure (IFP) in tumors (J. Ma, D. J. Waxman, Mol Cancer Ther 7, 3670 (2008)). Elevated IFP, in turn, results in increased resistance to convective transport of drug carriers in the tumor matrix and decreases the amount of drug reaching tumor cells (L. T. Baxter, R. K. Jain, Microvasc Res 37, 77 (1989)). This is especially true for central regions of the tumor, which are typically under-perfused. This is a critical problem because these poorly-perfused regions (which have low pH and low pO2) harbor the most aggressive and drug-resis...

example 2

[0116]Distribution of nutrients and drugs in most organs is governed by convective flow of blood to the organ and diffusion of the molecule in the organ. In solid tumors, this distribution is dictated by the tumor microenvironment and is highly irregular leading to regions lacking oxygen (hypoxia) and essential nutrients. These regions harbor cells that are most virulent and often responsible for tumor relapse and resistance; adequate drug levels are needed in these regions for complete remission.

[0117]Factors that affect intratumoral distribution include the tumor microenvironment (e.g., vascular architecture, ECM and IFP) and the physicochemical properties of drugs (e.g., size and charge). The rate of tumor cell growth is greater than the rate at which blood capillary cells proliferate. Accordingly, pro-angiogenic factors are not secreted uniformly throughout the tumor, which leads to abnormal vasculature that does not span the complete tumor volume. Additionally, the distribution...

example 3

Methods

[0139]Synthesis of streptokinase functionalized nanoparticles (SK NP). Poly-(lactide-co-glycolide) (PLGA) (Lactel Absorbable Polymers, USA) nanoparticles loaded with paclitaxel, coumarin-6 or SDB5491 were synthesized by a solvent evaporation technique. These nanoparticles were surface functionalized with a carboxyl terminated 10K-3.4K diblock co-polymer of poly-(lactide) (PLA) and poly-(ethylene glycol) (PEG) (Laysan Bio Inc. USA) and were synthesized as described by Patil, Y. B., et al., Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 2009. 30(5): p. 859-66.

[0140]For streptokinase conjugation, the nanoparticles were dispersed in deionized water (20 mg / mL). Catalysts, N-hydroxy sulfo-succinimide (sulfo-NHS) (Sigma Aldrich, USA) and 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) (Sigma Aldrich, USA) were added to this dispersion. A molar ratio of 10:1:: catalysts: block co-polymer was maintained. Af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Login to View More

Abstract

Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal.

Description

RELATED APPLICATION[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 61 / 593,707 filed on Feb. 1, 2012, which application is herein incorporated by reference.BACKGROUND OF THE INVENTION[0002]Inefficient transport of drug delivery systems through tumor extracellular matrix (ECM) severely limits therapeutic efficacy. Tumors are characterized by the presence of a neo-vasculature that is underdeveloped and leaky. This leads to deposition of fibrin, a key ingredient of blood clot, within the tumor matrix (M. Schafer, S. Werner, Nat Rev Mol Cell Biol 9, 628 (2008)). The presence of fibrin is an important cause of elevated interstitial fluid pressure (IFP) in tumors (J. Ma, D. J. Waxman, Mol Cancer Ther 7, 3670 (2008)). Elevated IFP, in turn, results in increased resistance to convective transport of drug carriers in the tumor matrix and decreases the amount of drug reaching tumor cells (L. T. Baxter, R. K. Jain, Microvasc Res 37, 77 (1989)). This is especia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/42A61K49/18A61K51/12A61K49/00
CPCA61K47/42A61K49/0089A61K49/1824A61K49/0093A61K47/48238A61K47/48915A61K51/1244A61K47/62A61K47/6937
Inventor PANYAM, JAYANTHSADHUKHA, TANMOYKIRTANE, AMEYA
Owner RGT UNIV OF MINNESOTA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com